Distal Esophageal Impedance Measured by High-resolution Esophageal Manometry With Impedance Suggests the Presence of Barrett's Esophagus.

Barrett esophagus Electric impedance Esophagitis Gastroesophageal reflux

Journal

Journal of neurogastroenterology and motility
ISSN: 2093-0879
Titre abrégé: J Neurogastroenterol Motil
Pays: Korea (South)
ID NLM: 101530189

Informations de publication

Date de publication:
30 07 2020
Historique:
received: 13 05 2019
revised: 03 07 2019
accepted: 18 12 2019
pubmed: 24 4 2020
medline: 24 4 2020
entrez: 24 4 2020
Statut: ppublish

Résumé

Barrett's esophagus (BE) is characterized by intestinal metaplasia in the distal esophagus. The aims of this study are to: (1) Compare baseline distal esophageal impedance (DEI) using high-resolution esophageal manometry with impedance (HREMI) in patients with BE, esophagitis, and healthy volunteers and (2) Correlate length of low impedance on HREMI in patients with BE to the length of endoscopic BE. Patients with BE or esophagitis who underwent HREMI were included. Ten volunteers had HREMI. Baseline DEI was calculated from HREMI using the landmark segment. In patients with BE, the impedance was plotted to measure the extent of plotted low impedance (PLI) and visual low impedance (VLI). Lengths of VLI and PLI were correlated to endoscopic length of BE by Prague score. Forty-five patients were included (16 BE; 19 esophagitis; 10 volunteers). BE patients had lower baseline DEI at the first, second, and third sensors above the lower esophageal sphincter (mean ± SEM: 1.37 ± 0.45, 0.97 ± 0.27, and 0.81 ± 0.20) compared to volunteers (8.73 ± 0.60, 8.20 ± 0.73, and 6.94 ± 0.99; Baseline DEI is lower in BE compared with esophagitis and healthy volunteers. The length of low impedance correlates to the endoscopic extent of BE. Thus, impedance values during HREMI may help suggest the presence and extent of BE or esophagitis.

Sections du résumé

Background/Aims
Barrett's esophagus (BE) is characterized by intestinal metaplasia in the distal esophagus. The aims of this study are to: (1) Compare baseline distal esophageal impedance (DEI) using high-resolution esophageal manometry with impedance (HREMI) in patients with BE, esophagitis, and healthy volunteers and (2) Correlate length of low impedance on HREMI in patients with BE to the length of endoscopic BE.
Methods
Patients with BE or esophagitis who underwent HREMI were included. Ten volunteers had HREMI. Baseline DEI was calculated from HREMI using the landmark segment. In patients with BE, the impedance was plotted to measure the extent of plotted low impedance (PLI) and visual low impedance (VLI). Lengths of VLI and PLI were correlated to endoscopic length of BE by Prague score.
Results
Forty-five patients were included (16 BE; 19 esophagitis; 10 volunteers). BE patients had lower baseline DEI at the first, second, and third sensors above the lower esophageal sphincter (mean ± SEM: 1.37 ± 0.45, 0.97 ± 0.27, and 0.81 ± 0.20) compared to volunteers (8.73 ± 0.60, 8.20 ± 0.73, and 6.94 ± 0.99;
Conclusions
Baseline DEI is lower in BE compared with esophagitis and healthy volunteers. The length of low impedance correlates to the endoscopic extent of BE. Thus, impedance values during HREMI may help suggest the presence and extent of BE or esophagitis.

Identifiants

pubmed: 32325542
pii: jnm19105
doi: 10.5056/jnm19105
pmc: PMC7329159
doi:

Types de publication

Journal Article

Langues

eng

Pagination

344-351

Références

Gastroenterology. 1996 Jul;111(1):85-92
pubmed: 8698230
J Gastroenterol. 2013 May;48(5):601-10
pubmed: 23076541
Clin Gastroenterol Hepatol. 2012 Oct;10(10):1110-6
pubmed: 22642956
Am J Gastroenterol. 2000 Nov;95(11):3089-96
pubmed: 11095322
Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1024-32
pubmed: 23708277
Am J Gastroenterol. 2005 Feb;100(2):265-9
pubmed: 15667480
Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:63-70; discussion 95-6
pubmed: 15456467
Curr Gastroenterol Rep. 2009 Jun;11(3):190-4
pubmed: 19463218
Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70
pubmed: 17431220
Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G376-83
pubmed: 12121885
Am J Gastroenterol. 2011 Dec;106(12):2093-7
pubmed: 21844921
Neurogastroenterol Motil. 2017 May;29(5):
pubmed: 27778419
Best Pract Res Clin Gastroenterol. 2008;22(4):661-9
pubmed: 18656823
Gut. 2011 Jul;60(7):885-92
pubmed: 21303918
Dig Dis Sci. 1992 Jun;37(6):849-56
pubmed: 1587189
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1075-81
pubmed: 25496815
Aliment Pharmacol Ther. 2007 Mar 1;25(5):629-36
pubmed: 17305764
Ann N Y Acad Sci. 1999 Apr 20;873:313-21
pubmed: 10372179

Auteurs

Rahul Kataria (R)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Benjamin Rosenfeld (B)

Department of Internal Medicine, Temple University Hospital, Philadelphia, PA, USA.

Zubair Malik (Z)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Martha Harrison (M)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Michael S Smith (MS)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Ron Schey (R)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Henry P Parkman (HP)

Division of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA.

Classifications MeSH